All subtypes of Influenza A (H1N1, H2N2 and H3N2 and H5N1). Specific for the nucleoprotein antigen. No cross-reactivity seen to Influenza B, Parainfluenza 1, 2 or Adenovirus or RSV.
Immunogen
Influenza A blend.
Application
Indirect immunofluorescence at 1:100-1:1000.
Optimal working dilutions must be determined by end user.
Research Category Infectious Diseases
Research Sub Category Infectious Diseases - Viral
This Anti-Influenza A Antibody, nucleoprotein, clones A1, A3 Blend is validated for use in IF for the detection of Influenza A.
Physical form
Ascites fluid containing no preservatives.
Unpurified
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control Influenza Control Slides, Catalogue Number 5010-5
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Infectious diseases and therapy, 7(2), 249-259 (2018-04-11)
Recent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 69, 78-80 (2015-07-26)
Influenza A/H5N1 actively circulated in Kamphaeng Phet (KPP), Thailand from 2004 to 2006. A prospective longitudinal cohort study of influenza virus infection in 800 adults conducted during 2008-2010 in KPP suggested that subclinical or mild H5N1 infections had occurred among
Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modeling.
Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.
McCullers, JA; Van De Velde, LA; Allison, KJ; Branum, KC; Webby, RJ; Flynn, PM
Clinical Infectious Diseases null
Tissue tropism of a Thailand strain of high-pathogenicity avian influenza virus (H5N1) in tissues of naturally infected native chickens (Gallus gallus), Japanese quail (Coturnix coturnix japonica) and ducks (Anas spp.).
Chongmas Antarasena, Rungtiva Sirimujalin, Porntip Prommuang, Stuart D Blacksell et al.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.